引用次数
引用: 97,128
H-指数: 136
I10-指数 : 357
出版物: 680
YES1 amplification as a primary driver of lung tumorigenesis and YES1/YAP1 amplifications as mediators of acquired resistance (AR) to ALK and EGFR tyrosine kinase inhibitors (TKIs).
Hiroki Sato , Daisuke Kubota , Paul K. Paik , Huan Qiao
Journal of Clinical Oncology 38 ( 15_suppl) e21591 -e21591
2020
Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers
Vivek Subbiah , Igor Puzanov , Jean-Yves Blay , Ian Chau
Cancer Discovery 10 ( 5) 657 -663
24
2020
Targeting ALK: Precision Medicine Takes on Drug Resistance
Jessica J. Lin , Gregory J. Riely , Alice T. Shaw
Cancer Discovery 7 ( 2) 137 -155
214
2017
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.
Emmet J. Jordan , Hyunjae R. Kim , Maria E. Arcila , David Barron
Cancer Discovery 7 ( 6) 596 -609
235
2017
Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers
Alexander Drilon , Romel Somwar , Biju P. Mangatt , Henrik Edgren
Cancer Discovery 8 ( 6) 686 -695
68
2018
Multidisciplinary management of thymic carcinoma.
Gregory J. Riely , James Huang , Andreas Rimner
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting ( 32) 466 -470
2012
Beyond "second-line" in non-small cell lung cancer: therapy and supportive care.
Renato G. Martins , Craig H. Reynolds , Gregory J. Riely
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 35 ( 35) 414 -418
2
2015
Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling
Jamie E. Chaft , Maria E. Arcila , Paul K. Paik , Christopher Lau
Molecular Cancer Therapeutics 11 ( 2) 485 -491
159
2012
Abstract CT025: Impact of the EML4-ALK fusion variant on the efficacy of lorlatinib in patients (pts) with ALK-positive advanced non-small cell lung cancer (NSCLC)
Todd M. Bauer , Jean-François Martini , Benjamin Besse , Chia-Chi Lin
Cancer Research 80
2020
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
Wee-Lee Yeo , Gregory J. Riely , Beow Y. Yeap , Michelle W. Lau
Journal of Thoracic Oncology 5 ( 7) 1048 -1053
86
2010
Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
Katharine A. Price , Christopher G. Azzoli , Lee M. Krug , Maria C. Pietanza
Journal of Thoracic Oncology 5 ( 10) 1623 -1629
95
2010
Insulin-Like Growth Factor-1 Receptor Expression in Thymic Malignancies
Nicolas Girard , Julie Teruya-Feldstein , Eden C. Payabyab , Gregory J. Riely
Journal of Thoracic Oncology 5 ( 9) 1439 -1446
38
2010
Induction Therapy For Locally Advanced Thymoma
Gregory J. Riely , James Huang
Journal of Thoracic Oncology 5 ( 10) S323 -S326
28
2010
Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans
Valerie W. Rusch , Marc Ladanyi , Mark G. Kris , J. Matthew Reinersman
Journal of Thoracic Oncology 6 ( 1) 28 -31
101
2011
Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing
Natasha Rekhtman , Suzanne M. Brandt , Carlie S. Sigel , Maria A. Friedlander
Journal of Thoracic Oncology 6 ( 3) 451 -458
200
2011
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D Travis , Elisabeth Brambilla , Masayuki Noguchi , Andrew G Nicholson
Journal of Thoracic Oncology 6 ( 2) 244 -285
5,395
2011
Chemotherapy Definitions and Policies for Thymic Malignancies
Nicolas Girard , Rohit Lal , Heather Wakelee , Gregory J. Riely
Journal of Thoracic Oncology 6 ( 7)
56
2011
Subtyping of Non-small Cell Lung Carcinoma: A Comparison of Small Biopsy and Cytology Specimens
Carlie S. Sigel , Andre L. Moreira , William D. Travis , Maureen F. Zakowski
Journal of Thoracic Oncology 6 ( 11) 1849 -1856
101
2011
A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations
Gregory J. Riely , Melissa L. Johnson , Chanoa Medina , Naiyer A. Rizvi
Journal of Thoracic Oncology 6 ( 8) 1435 -1437
99
2011
ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma.
Jamie E. Chaft , Natasha Rekhtman , Marc Ladanyi , Gregory J. Riely
Journal of Thoracic Oncology 7 ( 4) 768 -769
38
2012